| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. | Mol Cancer Ther | 2006 | 2.40 |
| 2 | Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. | Breast Cancer Res Treat | 2007 | 0.87 |
| 3 | Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. | Clin Cancer Res | 2004 | 0.87 |
| 4 | Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. | Curr Gene Ther | 2006 | 0.80 |
| 5 | Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications. | Methods Mol Biol | 2014 | 0.75 |